Companies / EMV

EMVISION MEDICAL DEVICES LTD

ASX:EMVHealth Care Equipment & Services
93.0M shares on issueASX (delayed) · as of 28 July 2026$1.60price · delayed$143.2Mmarket cap · indicative
B
Dilution grade

Runway 4–8 quarters; share count grew 9% in 24 months; 1 cash raise in 24 months

Cash runway4.6 quarters of funding
Share-count growth (24m)8.8%
Raise cadence (24m)1 cash raise
Options & rights overhang14.2% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

EMVISION MEDICAL DEVICES LTD's ordinary share count grew 8.8% between February 2024 and May 2026, to 93M shares. The company raised capital once in that period, with total disclosed proceeds of A$14.0M from a financing dated September 2025. Options and rights on issue could convert into 13M new shares, equal to 14.2% of the current share count, none of which are in the money at the current share price; the nearest expiry is June 2027. At the June 2026 quarter the company reported A$16.0M in available cash, equivalent to 4.6 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
14.2%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
4.6 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 93.0M per ASX (delayed) (28 July 2026).
87.1M89.2M91.4MDec 24Sept 25July 26Cash raise · 12 Sept 2025

Cash runway

4.6 qtrs
More than four quarters of funding at the recent spend rate.
$16.0M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
11 May 20262A · quoted issueEMV : ORDINARY FULLY PAID93.0MAppendix 2A
10 Apr 20263G · unquotedEMV : ORDINARY FULLY PAID92.9MAppendix 3G
6 Feb 20263G · unquotedEMV : ORDINARY FULLY PAID92.9MAppendix 3G
2 Jan 20263H · cancellationEMV : ORDINARY FULLY PAID92.9MAppendix 3H
1 Dec 20253H · cancellationEMV : ORDINARY FULLY PAID92.9MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$14.0M
Capital raise
12 Sept 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

14.2%
Total overhang · of current shares
0.0%
In the money · at current price
13.2M
Potential new shares
June 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
22 Apr 2026Carmel MonaghanBuy10k200k$18k3Y notice
31 Dec 2025Mr John KeepSell—300k—3Y notice
18 Nov 2025Carmel MonaghanOther—200k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

14 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
14 July 2026emu AI methods & insights published in npj Digital Medicine
26 May 2026$PAeromedical Study De-Risks Rural & Remote Stroke Use Cases
24 May 2026$PEMVision to Receive $1.17M IGP Grant Instalment
11 May 2026Cleansing Notice
11 May 2026Application for quotation of securities - EMV
10 May 2026$Pemu Pivotal Trial Expansion Adds Acute Ischaemia Detection
23 Apr 2026Change of Director's Interest Notice
12 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
10 Apr 2026Notification regarding unquoted securities - EMV
15 Mar 2026$P$3.8m R&D Rebate Received & Overseas Finding Approved
22 Feb 2026Half Yearly Presentation
22 Feb 2026$PHalf Yearly Report and Accounts
6 Feb 2026Notification regarding unquoted securities - EMV
27 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
26 Jan 2026$PStrong emu Clinical Trial & Program Progress
2 Jan 2026Notification of cessation of securities - EMV
2 Jan 2026Change of Director's Interest Notice x4
1 Dec 2025Notification of cessation of securities - EMV
26 Nov 2025$PFirst Responder Aeromedical Study Commences

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.